Key words: recombinant vaccinia virus strain; glioblastoma; GL261 cell line; immune cells; tumor microenvironment; natural killer cells; tumor-infiltrating lymphocytes.
- Abstract
- References
- How to cite
Glioblastoma is a highly aggressive and currently incurable brain tumor. It is characterized by a pronounced immunosuppressive tumor microenvironment (TME), which limits the potential of any immunotherapy options. Targeted therapy with recombinant oncolytic viruses can modulate the properties of the TME, overcome the glioblastoma-mediated immunosuppression, and evoke an antitumor immune response. Recombinant vaccinia viruses are suitable for these tasks because they have a favorable safety profile and can be modified with cDNA of immunomodulatory factors for their expression in tumor cells.
The aim of the study was to evaluate the impact of the recombinant vaccinia virus strain carrying the interleukin-15 cDNA (LIVP-mIL15) on the TME in the GL261 experimental glioma model.
Materials and Methods. Using intravital fluorescence microscopy, in vivo bioluminescence imaging, brain magnetic resonance imaging, and flow cytometry of immune cell subpopulations, we evaluated the ability of the novel LIVP-mIL15 strains (LIVP-mIL15-RFP and LIVP-mIL15-FLuc) to affect GL261 glioma cells in 3D spheroids and in the syngeneic orthotopic GL261 glioma in C57BL/6 mice, as well as the dynamics of TME changes induced by immunotherapy.
Results. The recombinant vaccinia virus strain LIVP-mIL15-RFP is capable of efficiently infecting GL261 glioma cells in 3D spheroids formed during cultivation in non-adherent plates and of inducing selective transgene expression in orthotopic glioma cells following a single stereotactic or intravenous administration. The bioluminescence signal of the recombinant vaccinia virus strain LIVP-mIL15-FLuc was detected in the tumor at 48, 72, and 144 h after stereotactic administration and at 72 h after intravenous virus administration. Stereotactic administration of LIVP-mIL15-RFP caused changes in the composition of immune cell subpopulations, with a relative increase in the proportion of IL-15-responsive NK cells and cytotoxic lymphocytes within the TME.
1. Grochans S., Cybulska A.M., Simińska D., Korbecki J., Kojder K., Chlubek D., Baranowska-Bosiacka I. Epidemiology of glioblastoma multiforme — literature review. Cancers (Basel) 2022; 14(10): 2412, https://doi.org/10.3390/cancers14102412.
2. Sipos D., Raposa B.L., Freihat O., Simon M., Mekis N., Cornacchione P., Kovács Á. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers (Basel) 2025; 17(1): 146, https://doi.org/10.3390/cancers17010146.
3. Weller M., van den Bent M., Preusser M., Le Rhun E., Tonn J.C., Minniti G., Bendszus M., Balana C., Chinot O., Dirven L., French P., Hegi M.E., Jakola A.S., Platten M., Roth P., Rudà R., Short S., Smits M., Taphoorn M.J.B., von Deimling A., Westphal M., Soffietti R., Reifenberger G., Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18(3): 170–186, https://doi.org/10.1038/s41571-020-00447-z.
4. Xiao Z.Z., Wang Z.F., Lan T., Huang W.H., Zhao Y.H., Ma C., Li Z.Q. Carmustine as a supplementary therapeutic option for glioblastoma: a systematic review and meta-analysis. Front Neurol 2020; 11: 1036, https://doi.org/10.3389/fneur.2020.01036.
5. Ren X., Ai D., Li T., Xia L., Sun L. Effectiveness of lomustine combined with bevacizumab in glioblastoma: a meta-analysis. Front Neurol 2020; 11: 603947, https://doi.org/10.3389/fneur.2020.603947.
6. Loras A., Gonzalez-Bonet L.G., Gutierrez-Arroyo J.L., Martinez-Cadenas C., Marques-Torrejon M.A. Neural stem cells as potential glioblastoma cells of origin. Life (Basel) 2023; 13(4): 905, https://doi.org/10.3390/life13040905.
7. Bakhshinyan D., Savage N., Salim S.K., Venugopal C., Singh S.K. The strange case of jekyll and hyde: parallels between neural stem cells and glioblastoma-initiating cells. Front Oncol 2020; 10: 603738, https://doi.org/10.3389/fonc.2020.603738.
8. Sloan A.R., Silver D.J., Kint S., Gallo M., Lathia J.D. Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going? Neuro Oncol 2024; 26(5): 785–795, https://doi.org/10.1093/neuonc/noae011.
9. Dirkse A., Golebiewska A., Buder T., Nazarov P.V., Muller A., Poovathingal S., Brons N.H.C., Leite S., Sauvageot N., Sarkisjan D., Seyfrid M., Fritah S., Stieber D., Michelucci A., Hertel F., Herold-Mende C., Azuaje F., Skupin A., Bjerkvig R., Deutsch A., Voss-Böhme A., Niclou S.P. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun 2019; 10(1): 1787, https://doi.org/10.1038/s41467-019-09853-z.
10. Bugakova A.S., Chudakova D.A., Myzina M.S., Yanysheva E.P., Ozerskaya I.V., Soboleva A.V., Baklaushev V.P., Yusubalieva G.M. Non-tumor cells within the tumor microenvironment — the “eminence grise” of the glioblastoma pathogenesis and potential targets for therapy. Cells 2024; 13(10): 808, https://doi.org/10.3390/cells13100808.
11. Chaurasiya S., Chen N.G., Warner S.G. Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers (Basel) 2018; 10(4): 124, https://doi.org/10.3390/cancers10040124.
12. Qi Z., Long X., Liu J., Cheng P. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Front Cell Neurosci 2022; 16: 819363, https://doi.org/10.3389/fncel.2022.819363.
13. Zhao B., Wu J., Li H., Wang Y., Wang Y., Xing H., Wang Y., Ma W. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma. Cell Commun Signal 2023; 21(1): 74, https://doi.org/10.1186/s12964-023-01098-0.
14. El Atat O., Naser R., Abdelkhalek M., Habib R.A., El Sibai M. Molecular targeted therapy: a new avenue in glioblastoma treatment. Oncol Lett 2023; 25(2): 46, https://doi.org/10.3892/ol.2022.13632.
15. Yasinjan F., Xing Y., Geng H., Guo R., Yang L., Liu Z., Wang H. Immunotherapy: a promising approach for glioma treatment. Front Immunol 2023; 14: 1255611, https://doi.org/10.3389/fimmu.2023.1255611.
16. Rios S.A., Oyervides S., Uribe D., Reyes A.M., Fanniel V., Vazquez J., Keniry M. Emerging therapies for glioblastoma. Cancers (Basel) 2024; 16(8): 1485, https://doi.org/10.3390/cancers16081485.
17. Wang J., Cazzato E., Ladewig E., Frattini V., Rosenbloom D.I., Zairis S., Abate F., Liu Z., Elliott O., Shin Y.J., Lee J.K., Lee I.H., Park W.Y., Eoli M., Blumberg A.J., Lasorella A., Nam D.H., Finocchiaro G., Iavarone A., Rabadan R. Clonal evolution of glioblastoma under therapy. Nat Genet 2016; 48(7): 768–776, https://doi.org/10.1038/ng.3590.
18. Stepanenko A.A., Sosnovtseva A.O., Valikhov M.P., Chernysheva A.A., Abramova O.V., Naumenko V.A., Chekhonin V.P. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy. Front Immunol 2024; 15: 1326757, https://doi.org/10.3389/fimmu.2024.1326757.
19. De Munck J., Binks A., McNeish I.A., Aerts J.L. Oncolytic virus-induced cell death and immunity: a match made in heaven? J Leukoc Biol 2017; 102(3): 631–643, https://doi.org/10.1189/jlb.5RU0117-040R.
20. Zhang Q., Liu F. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Cell Death Dis 2020; 11(6): 485, https://doi.org/10.1038/s41419-020-2696-5.
21. Sun Y., Zhang Z., Zhang C., Zhang N., Wang P., Chu Y., Chard Dunmall L.S., Lemoine N.R., Wang Y. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. Mol Ther Oncolytics 2022; 26: 105–119, https://doi.org/10.1016/j.omto.2022.05.008.
22. Hamad A., Yusubalieva G.M., Baklaushev V.P., Chumakov P.M., Lipatova A.V. Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses 2023; 15(2): 547, https://doi.org/10.3390/v15020547.
23. Foreman P.M., Friedman G.K., Cassady K.A., Markert J.M. Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics 2017; 14(2): 333–344, https://doi.org/10.1007/s13311-017-0516-0.
24. Martikainen M., Essand M. Virus-based immunotherapy of glioblastoma. Cancers (Basel) 2019; 11(2): 186, https://doi.org/10.3390/cancers11020186.
25. Ageenko A., Vasileva N., Richter V., Kuligina E. Combination of oncolytic virotherapy with different antitumor approaches against glioblastoma. Int J Mol Sci 2024; 25(4): 2042, https://doi.org/10.3390/ijms25042042.
26. Webb M.J., Sener U., Vile R.G. Current status and challenges of oncolytic virotherapy for the treatment of glioblastoma. Pharmaceuticals (Basel) 2023; 16(6): 793, https://doi.org/10.3390/ph16060793.
27. Mokhtarpour K., Akbarzadehmoallemkolaei M., Rezaei N. A viral attack on brain tumors: the potential of oncolytic virus therapy. J Neurovirol 2024; 30(3): 229–250, https://doi.org/10.1007/s13365-024-01209-8.
28. Shakiba Y., Vorobyev P.O., Yusubalieva G.M., Kochetkov D.V., Zajtseva K.V., Valikhov M.P., Kalsin V.A., Zabozlaev F.G., Semkina A.S., Troitskiy A.V., Baklaushev V.P., Chumakov P.M., Lipatova A.V. Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response. Mol Ther Oncolytics 2023; 29: 158–168, https://doi.org/10.1016/j.omto.2023.05.002.
29. Shakiba Y., Vorobyev P.O., Naumenko V.A., Kochetkov D.V., Zajtseva K.V., Valikhov M.P., Yusubalieva G.M., Gumennaya Y.D., Emelyanov E.A., Semkina A.S., Baklaushev V.P., Chumakov P.M., Lipatova A.V. Oncolytic efficacy of a recombinant vaccinia virus strain expressing bacterial flagellin in solid tumor models. Viruses 2023; 15(4): 828, https://doi.org/10.3390/v15040828.
30. Yusubalieva G.M., Chudakova D.A., Shirokikh P.G., Yuzhakova D.V., Kiseleva E.B., Sachkova D.A., Dudenkova V.V., Kirsova D.P., Myzina M.S., Yanysheva E.P., Panov A.V., Zakirova N.F., Poteryakhina A.V., Semikhin A.S., Kalinkin A.A., Baklaushev V.P. Multiparametric detection of effects of TILs and oncolytic virotherapy on xenograft mouse model of glioblastoma. Biomedicines 2025; 13(12): 2977, https://doi.org/10.3390/biomedicines13122977.
31. Szatmári T., Lumniczky K., Désaknai S., Trajcevski S., Hídvégi E.J., Hamada H., Sáfrány G. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97(6): 546–553, https://doi.org/10.1111/j.1349-7006.2006.00208.x.
32. Letchuman V., Ampie L., Shah A.H., Brown D.A., Heiss J.D., Chittiboina P. Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes. Neurosurg Focus 2022; 52(2): E5, https://doi.org/10.3171/2021.11.FOCUS21556.
33. Pouyan A., Ghorbanlo M., Eslami M., Jahanshahi M., Ziaei E., Salami A., Mokhtari K., Shahpasand K., Farahani N., Meybodi T.E., Entezari M., Taheriazam A., Hushmandi K., Hashemi M. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer 2025; 24(1): 58, https://doi.org/10.1186/s12943-025-02267-0.
34. Haddad A.F., Young J.S., Amara D., Berger M.S., Raleigh D.R., Aghi M.K., Butowski N.A. Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv 2021; 3(1): vdab100, https://doi.org/10.1093/noajnl/vdab100.
35. Beerli C., Yakimovich A., Kilcher S., Reynoso G.V., Fläschner G., Müller D.J., Hickman H.D., Mercer J. Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility. Nat Microbiol 2019; 4(2): 216–225, https://doi.org/10.1038/s41564-018-0288-2.
36. Berger C., Berger M., Hackman R.C., Gough M., Elliott C., Jensen M.C., Riddell S.R. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114(12): 2417–2426, https://doi.org/10.1182/blood-2008-12-189266.
37. Waldmann T.A., Lugli E., Roederer M., Perera L.P., Smedley J.V., Macallister R.P., Goldman C.K., Bryant B.R., Decker J.M., Fleisher T.A., Lane H.C., Sneller M.C., Kurlander R.J., Kleiner D.E., Pletcher J.M., Figg W.D., Yovandich J.L., Creekmore S.P. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011; 117(18): 4787–4795, https://doi.org/10.1182/blood-2010-10-311456.
38. Isaacs S.N., Kotwal G.J., Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci U S A 1992; 89(2): 628–632, https://doi.org/10.1073/pnas.89.2.628.
39. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156(4): 1363–1380, https://doi.org/10.1016/S0002-9440(10)65006-7.
40. Kober C., Rohn S., Weibel S., Geissinger U., Chen N.G., Szalay A.A. Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps. J Transl Med 2015; 13: 216, https://doi.org/10.1186/s12967-015-0586-x.
41. Liew P.X., Kubes P. The neutrophil's role during health and disease. Physiol Rev 2019; 99(2): 1223–1248, https://doi.org/10.1152/physrev.00012.2018.
42. Naumenko V., Turk M., Jenne C.N., Kim S.J. Neutrophils in viral infection. Cell Tissue Res 2018; 371(3): 505–516, https://doi.org/10.1007/s00441-017-2763-0.
43. Townsley A.C., Weisberg A.S., Wagenaar T.R., Moss B. Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway. J Virol 2006; 80(18): 8899–8908, https://doi.org/10.1128/JVI.01053-06.
44. Mathupala S.P., Colen C.B., Parajuli P., Sloan A.E. Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr 2007; 39(1): 73–77, https://doi.org/10.1007/s10863-006-9062-x.
45. Schlee M., Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol 2016; 16(9): 566–580, https://doi.org/10.1038/nri.2016.78.
46. Ames E., Canter R.J., Grossenbacher S.K., Mac S., Chen M., Smith R.C., Hagino T., Perez-Cunningham J., Sckisel G.D., Urayama S., Monjazeb A.M., Fragoso R.C., Sayers T.J., Murphy W.J. NK cells preferentially target tumor cells with a cancer stem cell phenotype. J Immunol 2015; 195(8): 4010–4019, https://doi.org/10.4049/jimmunol.1500447.
47. Haspels H.N., Rahman M.A., Joseph J.V., Gras Navarro A., Chekenya M. Glioblastoma stem-like cells are more susceptible than differentiated cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors-human leukocyte antigen ligand mismatch and activation receptor-ligand interactions. Front Immunol 2018; 9: 1345, https://doi.org/10.3389/fimmu.2018.01345.
48. Sedgwick A.J., Ghazanfari N., Constantinescu P., Mantamadiotis T., Barrow A.D. The role of NK cells and innate lymphoid cells in brain cancer. Front Immunol 2020; 11: 1549, https://doi.org/10.3389/fimmu.2020.01549.
49. Paul S., Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol 2017; 8: 1124, https://doi.org/10.3389/fimmu.2017.01124.
50. Wang W., Liu Y., He Z., Li L., Liu S., Jiang M., Zhao B., Deng M., Wang W., Mi X., Sun Z., Ge X. Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discov 2024; 10(1): 40, https://doi.org/10.1038/s41420-024-01815-9.
51. Sheppard S., Sun J.C. Virus-specific NK cell memory. J Exp Med 2021; 218(4): e20201731, https://doi.org/10.1084/jem.20201731.
52. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C., Joyce S., Peschon J.J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191(5): 771–780, https://doi.org/10.1084/jem.191.5.771.
53. Cooper M.A., Bush J.E., Fehniger T.A., VanDeusen J.B., Waite R.E., Liu Y., Aguila H.L., Caligiuri M.A. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100(10): 3633–3638, https://doi.org/10.1182/blood-2001-12-0293.